• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

    11/14/24 4:17:44 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $EPRX alert in real time by email
    SC 13G 1 b81067919.htm SCHEDULE 13G



     
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     
     
     
     
    Eupraxia Pharmaceuticals Inc.
         
         
    (Name of Issuer)
     
     
    Common Shares
         
         
     
    (Title of Class of Securities)
     
     
    29842P105
         
         
     
    (CUSIP Number)
     
     
    September 30, 2024
         
         
    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    □              Rule 13d-1(b)
    □              Rule 13d-1(c)
    ☒             Rule 13d-1(d)
     
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     



    CUSIP No. 29842P105
    SCHEDULE 13G
    Page 2 of 5 Pages




    1
    NAMES OF REPORTING PERSONS
     
    Robert Disbrow
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    3,092,500 (1)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    3,092,500 (1)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    3,092,500 (1)
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.6% (1) (2)
    12
    TYPE OF REPORTING PERSON
     
    IN
    (1) Includes (a) 2,592,500 shares of the Issuer’s (as defined below) common shares, with no par value (the “Common Shares”) and 200,000 Common Shares underlying Issuer’s Series 1 preferred shares, with no par value (the “Preferred Shares”) jointly owned by Robert Disbrow and Kim Kawaguchi, husband and wife (the “Disbrows”); and (b) 300,000 Common Shares held by the children of the Disbrows. The Disbrows disclaim beneficial ownership of the Common Shares held by their children.
    (2) Calculated based on the Common Shares and Preferred Shares, beneficially owned by the Reporting Person relative to the Issuer’s 35,622,553 outstanding Common Shares, as of June 30, 2024, as reported in the Issuer’s Form 6-K filed with the SEC on August 7, 2024, plus the 200,000 Preferred Shares.




    Item 1(a)
    Name of Issuer:
       
     
    Eupraxia Pharmaceuticals Inc.
       
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:
       
     
    201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5GR.
       
    Items 2(a)
    Name of Person Filing:
       
     
    This Schedule 13G is being filed by Robert Disbrow (the “Reporting Person”).
       
    Item 2(b)
    Address of Principal Business Office:
     
    The business address of the  Reporting Person is:
     
    200 Burrard Street, Suite 700
     
    Vancouver, BC V6C 3L6
       
    Item 2(c)
    Citizenship:
       
     
    Robert Disbrow is a citizen of Canada.
       
    Item 2(d)
    Title of Class of Securities:
       
     
    Common shares, with no par value (“Common Shares”)
       
    Item 2(e)
    CUSIP Number:
       
     
    29842P105
       
    Item 3
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:
       
     
    (a)
    ☐ Broker or dealer registered under Section 15 of the Act;
     
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act;
     
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act;
     
    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
     
    (e)
    ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     
    (f)
    ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
     
    (g)
    ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
     
    (h)
    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
     
    (j)
    ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
     
    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).


     



    Item 4
    Ownership:
       
     
    The information required by Items 4(a)-(c), as of the date hereof, is set forth in Rows 5-11 of the cover page hereto for each Select Reporting Person and is incorporated herein by reference for each such Select Reporting Person.
       
       
    Item 5
    Ownership of Five Percent or Less of a Class:
       
     
    If this statement is being filed to report the fact that as of the date hereof a reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐ .
       
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person:
       
     
    N/A
       
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
     
    N/A
       
    Item 8
    Identification and Classification of Members of the Group:
       
     
    N/A
       
    Item 9
    Notice of Dissolution of Group:
       
     
    N/A
       
    Item 10
    Certification:
       
     
    N/A
       
       


    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
     
     
     
    Dated: November 14, 2024
     
       /s/ Robert Disbrow
     
    Robert Disbrow






    Get the next $EPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EPRX

    DatePrice TargetRatingAnalyst
    2/21/2025$12.00Buy
    Craig Hallum
    11/14/2024$9.00Buy
    Rodman & Renshaw
    More analyst ratings

    $EPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Eupraxia Pharmaceuticals Announces CFO Succession

      -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. "Having previously served as Eupraxia's CFO

      2/18/25 7:00:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

      VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the "Preferred Shares"), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the "Private Placement").

      10/31/24 7:36:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    Financials

    Live finance-specific insights

    See more
    • Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

      Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

      5/6/25 6:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

      VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-

      3/20/25 5:30:48 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

      VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the third quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the third quarter, we advanced our Phase 1b/2a RESOLVE trial for EP-104GI as a treatment for eosinophilic esophagitis, reporting further positiv

      11/7/24 5:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    SEC Filings

    See more
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      5/7/25 2:15:04 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      5/6/25 4:59:51 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      5/5/25 7:15:04 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Eupraxia Pharmaceuticals with a new price target

      Craig Hallum initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      2/21/25 8:14:31 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Rodman & Renshaw initiated coverage on Eupraxia Pharmaceuticals with a new price target

      Rodman & Renshaw initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      11/14/24 7:29:37 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

      VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that it will host a virtual key opinion leader (KOL) event on Friday, May 9, 2025 at 9:00 AM ET. To register, click here. The event will feature Evan Dellon, MD, MPH (University of North Carolina, Chapel Hill), who will join Company management to discuss additional clinical data from Eupraxia's Phase 1b/2a RESOLVE Study evaluating EP-104GI for the treatment of

      5/7/25 2:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

      Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

      5/6/25 6:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

      Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GIAt 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoEAlso, at 9 months patients demonstrated sustained or improved treatment outcomes compared to 3- and 6-month resultsAdditional long-term data to be released with higher doses in Q3 2025Eupraxia to host webinar with guest, Dr. Evan Dellon, to discuss data from RESOLVE trial on Fri

      5/5/25 7:00:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

      SC 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

      11/14/24 4:17:44 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D filed by Eupraxia Pharmaceuticals Inc.

      SC 13D - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

      11/7/24 4:10:15 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care